StreetInsider.com News Articles

Form PRE 14A CDT Equity Inc. For: Oct 16

Fri, 16 Oct 2026 16:53:00 -0400

si-local-file:///var/storage/secattach/20261016/27198491.html

CDT Highlights Sarborg's Solid-Form Patent Filing on a First-in-Class Respiratory Asset

Wed, 14 Oct 2026 08:10:23 -0400

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Oct. 14, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) ("CDT" or the "Company") today notes the announcement from Sarborg Limited regarding intellectual property covering novel solid forms of a major, first-in-class respiratory medicine, an asset class addressing a treatment market estimated at more than $20 billion annually.

“Sarborg has now built a valuable portfolio of patented solid-form assets, and this filing strengthens its asset base and its prospects as it builds a data package to support licensing and partnership discussions,” said James Bligh, Chief Executive Officer of

CDT Highlights Sarborg's Solid-Form Patent Filing on a First-in-Class Respiratory Asset

Wed, 14 Oct 2026 08:10:23 -0400

CDT Highlights Sarborg's Solid-Form Patent Filing on a First-in-Class Respiratory Asset

Wed, 14 Oct 2026 08:10:00 -0400

CDT Highlights Sarborg's Solid-Form Patent Filing on a First-in-Class Respiratory Asset

Wed, 14 Oct 2026 08:10:00 -0400

Form 424B3 CDT Equity Inc.

Tue, 13 Oct 2026 08:05:00 -0400

si-local-file:///var/storage/secattach/20261013/27177587.html

Form 8-K CDT Equity Inc. For: Oct 06

Tue, 13 Oct 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20261013/27177422.html

Form SCHEDULE 13G/A CDT Equity Inc. Filed by: Primary Development Fund (Cayman) SPC - E3 Fund SP

Thu, 08 Oct 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20261008/27167029.html

Form SCHEDULE 13G/A CDT Equity Inc. Filed by: Taylor Mark Andrew

Wed, 07 Oct 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20261007/27161271.html

Form SCHEDULE 13G CDT Equity Inc. Filed by: Primary Development Fund (Cayman) SPC - E3 Fund SP

Wed, 07 Oct 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20261007/27161284.html

Form SCHEDULE 13G/A CDT Equity Inc. Filed by: Wigglesworth Craig Stuart

Wed, 07 Oct 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20261007/27161261.html

Form 424B3 CDT Equity Inc.

Fri, 02 Oct 2026 08:36:00 -0400

si-local-file:///var/storage/secattach/20261002/27139245.html

Sarborg files quantum computing IP for drug discovery; CDT holds 22.7% stake

Tue, 29 Sep 2026 07:02:46 -0400

CDT Equity Inc. (NASDAQ: CDT) announced that Sarborg Limited, in which CDT holds a 22.7% stake, has filed new intellectual property applying quantum sampling to disease biology and drug discovery, according to a press release from CDT.

CDT holds 1,290 shares in Sarborg. Sarborg's latest capital raise was priced at $125,000 per share, implying a fully diluted valuation of approximately $709 million.

Sarborg's filing focuses on applying quantum computation to disease gene networks — the regulators that switch disease genes on and off — rather than simulating individual molecules, which the company says is the focus of existing quantum computing work in

CDT Highlights Sarborg’s Expanding Quantum Computing IP Portfolio and Application to Drug Discovery

Tue, 29 Sep 2026 07:00:00 -0400

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept. 29, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) today notes the announcement from Sarborg Limited regarding the filing of new intellectual property applying quantum sampling to disease biology and drug discovery. CDT holds 1,290 shares in Sarborg, representing 22.7% of the issued share capital. Sarborg’s latest capital raise was at $125,000 per share, implying a fully diluted valuation of approximately $709 million.

A copy of Sarborg’s full announcement is available below and at www.sarborg.com/news.

Sarborg Expands Quantum Computing

CDT Highlights Sarborg’s Expanding Quantum Computing IP Portfolio and Application to Drug Discovery

Tue, 29 Sep 2026 07:00:00 -0400

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept. 29, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) today notes the announcement from Sarborg Limited regarding the filing of new intellectual property applying quantum sampling to disease biology and drug discovery. CDT holds 1,290 shares in Sarborg, representing 22.7% of the issued share capital. Sarborg’s latest capital raise was at $125,000 per share, implying a fully diluted valuation of approximately $709 million.

A copy of Sarborg’s full announcement is available below and at www.sarborg.com/news.

Sarborg Expands Quantum Computing

Form 8-K CDT Equity Inc. For: Sep 24

Fri, 25 Sep 2026 08:15:00 -0400
si-local-file:///var/storage/secattach/20260925/27104341.html

CDT Equity announces 1-for-25 reverse stock split on Nasdaq

Fri, 25 Sep 2026 08:10:13 -0400

CDT Equity Inc. (Nasdaq: CDT), a biopharmaceutical development company, announced that its board of directors has approved a 1-for-25 reverse stock split of its common stock, citing the need to maintain compliance with Nasdaq's bid-price rule.

The reverse stock split became effective September 28, 2026, at 5:00 p.m. Eastern Time. The company's common stock began trading on an adjusted basis on the Nasdaq Capital Market on September 29, 2026, under the existing ticker symbol "CDT" with a new CUSIP number of 20678X700.

Under the terms of the split, every 25 shares of issued and outstanding common stock were combined into one share.

CDT Equity Inc. Announces Reverse Stock Split

Fri, 25 Sep 2026 08:10:00 -0400

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept. 25, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), announces that its board of directors has approved a 1-for-25 reverse stock split of the Company’s common stock, to ensure continued compliance with the Nasdaq bid-price rule. The Company’s stockholders approved future reverse stock splits, their timing, and granted the board of directors authority to determine future exact split ratios.

The reverse stock split will become effective on September 28, 2026, at 5:00 pm, Eastern Time (the “Effective Time”), and the Company’s common stock

CDT Equity Inc. Announces Reverse Stock Split

Fri, 25 Sep 2026 08:10:00 -0400

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept. 25, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), announces that its board of directors has approved a 1-for-25 reverse stock split of the Company’s common stock, to ensure continued compliance with the Nasdaq bid-price rule. The Company’s stockholders approved future reverse stock splits, their timing, and granted the board of directors authority to determine future exact split ratios.

The reverse stock split will become effective on September 28, 2026, at 5:00 pm, Eastern Time (the “Effective Time”), and the Company’s common stock

Form 424B3 CDT Equity Inc.

Fri, 18 Sep 2026 17:20:00 -0400
si-local-file:///var/storage/secattach/20260918/27081318.html

Form 8-K CDT Equity Inc. For: Sep 14

Fri, 18 Sep 2026 17:16:00 -0400
si-local-file:///var/storage/secattach/20260918/27081296.html

Form 424B3 CDT Equity Inc.

Fri, 18 Sep 2026 16:30:00 -0400
si-local-file:///var/storage/secattach/20260918/27080870.html

CDT Equity partners with QIMA to test tapinarof drug combinations

Fri, 18 Sep 2026 06:30:27 -0400

CDT Equity Inc. (Nasdaq: CDT) announced a partnership with QIMA Life Sciences, a preclinical dermatology contract research organization, to evaluate combinations of tapinarof in psoriasis and vitiligo, according to a press release dated Sept. 18, 2026.
Initial studies will focus on tapinarof, sold under the brand name VTAMA®, which is currently approved for plaque psoriasis and atopic dermatitis in the U.S. and Japan. CDT holds a portfolio of patents around tapinarof, including solid form and method-of-use patents in combination with other drugs. QIMA will test these combinations using skin tissue from psoriatic patients to assess the potential for a second-generation tapinarof

CDT Partners with QIMA Life Sciences to Evaluate Novel Tapinarof Combinations in Psoriasis and Vitiligo

Fri, 18 Sep 2026 06:30:00 -0400

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept. 18, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announced that it has entered into a partnership with QIMA Life Sciences, a world leading preclinical dermatology CRO, to explore the potential of several of CDT’s assets in autoimmune skin diseases.

CDT plans to leverage QIMA’s unique access to human skin from both healthy donors and patients. The use of patient tissue offers the most clinically relevant data possible, providing rapid translation to clinic and providing potential license partners the highest level of confidence possible

CDT Partners with QIMA Life Sciences to Evaluate Novel Tapinarof Combinations in Psoriasis and Vitiligo

Fri, 18 Sep 2026 06:30:00 -0400

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept. 18, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announced that it has entered into a partnership with QIMA Life Sciences, a world leading preclinical dermatology CRO, to explore the potential of several of CDT’s assets in autoimmune skin diseases.

CDT plans to leverage QIMA’s unique access to human skin from both healthy donors and patients. The use of patient tissue offers the most clinically relevant data possible, providing rapid translation to clinic and providing potential license partners the highest level of confidence possible